Read the research behind the results
The Apollo wearable’s efficacy has been validated in a number of independent and university-led trials, and there are more studies in progress focused on stress-related conditions. The Apollo Neuro team is excited to share these promising results in our mission to help people take control of their stress and live healthier, happier lives.
🎖️We are proud to share that two of our studies are double-blind randomized placebo controlled crossover trials.
What does that mean? A double-blind randomized placebo-controlled crossover trial is the gold-standard in scientific methodology. These studies are accepted as producing results that are untainted by bias. The sample size in these rigorous trials are more powerful than a study that simply compares two groups. Each subject in a double-blind randomized placebo-controlled crossover trial is exposed to every condition of the trial multiple times.
Completed studies and preliminary results
NEW: Wearable in Systemic Sclerosis: A Pilot Study of the Apollo Wearable Demonstrates Improvement in Fatigue, Raynaud Phenomenon and Quality-of-Life in Patients with Systemic Sclerosis
Partner
University of Pittsburgh Medical Center
Results
After 4 weeks of using the Apollo wearable, participants reported less fatigue (p <0.001). The average daily number of Reynaud attacks declined (p < 0.01), as did the Raynaud condition score (p<0.001) after 4 weeks of use. Average device usage (2.87 hours per day) far exceeded the requested time, and no adverse events occurred. Improvements were also observed in quality of life (QoL) in physical function (p <0.01), sleep disturbance (p = 0.001), and ability to participate in social roles and activities (p < 0.001). Significant improvements were also noted for depression (p < 0.01) and disability (p < 0.05) measures.
Population
Systemic Sclerosis patients
Sample size
25
Apollo vibrations improve HRV in a double-blind randomized placebo-controlled crossover trial
Partner
University of Pittsburgh
Results
Statistically significant increase in HRV
Population
University of Pittsburgh club and varsity athletes
Sample size
22
Primary outcomes
Improved HRV, Faster recovery
🎖️Double-blind randomized placebo controlled crossover trial
Real-world observational study of Apollo to improve sleep and cardiovascular metrics
Preliminary results
Those who use the Apollo wearable consistently (3+ hours a day, 5+ days a week, during the day and night) over 3 months see the biggest improvements in sleep and cardiovascular recovery metrics.
Population
Apollo wearable users (18+)
Sample size
582
Primary outcomes
Sleep quality and cardiovascular metrics (heart rate, HRV) as measured by ŌURA Ring
*This study is sponsored by Apollo Neuro
Double-blind randomized placebo-controlled crossover study of Apollo to improve HRV and cognitive performance
Partner
University of Pittsburgh
Results
In a double-blind randomized placebo-controlled crossover clinical trial, Apollo vibrations improved heart rate variability (HRV) and cognitive performance under stress.
Population
Healthy adults (18+)
Sample size
38
Primary outcomes
Cognitive performance
Secondary outcomes
HRV, self-reported stress, pupil dilation, galvanic skin response, respirations, EEG
🎖️Double-blind randomized placebo controlled crossover trial
Open-label trial of Apollo to improve access to meditative states
Partner
University of Pittsburgh
Results
Both experienced and naive meditators achieve significantly deeper meditative states with the Apollo wearable.
Population
Healthy adults (18+)
Sample size
50 (25 experienced meditators, 25 without meditation experience)
Primary outcomes
Positive affect, HRV
Secondary outcomes
Negative affect, task performance, EEG
Pilot study of Apollo in nurses to reduce stress and signs of burnout
Partner
Skilled nursing facility • Pittsburgh, PA
Results
In an open-label evaluation to improve employee wellness and quality of care in nursing home staff, the Apollo wearable reduced stress in nursing staff by up to 40% in two weeks.
Population
Nurses
Sample size
12
Primary outcome
Quality of life, mood, and stress symptoms
Pilot study of Apollo to improve focus and calm in children with ADHD and anxiety disorders
Partner
Children’s Integrated Center for Success (CICS)
Results
Neurodevelopmental pediatrics pilot study shows improvement in mood, behavior, engagement, and stress reduction in children and adolescents with anxiety and ADHD.
Population
Pediatrics age 7-17 across a breadth of diagnostic categories, like mood and anxiety disorders, as well as impulse control, autism, and ADHD
Sample size
15
Primary outcome
Mood & behavior, stress reduction, engagement
Pilot study of Apollo to improve athletic performance, recovery, and HRV
Partner
Division 1 University Athletics Department
Results
In a study of collegiate athletes, the Apollo wearable improved heart rate variability (HRV), athletic performance and recovery.
Population
Collegiate athletes (18+)
Sample size
40
Primary outcomes
Athletic performance and recovery, cardiovascular metrics (HRV, heart rate)
Open-label trial of Apollo to improve symptoms in patients with PTSD
Partner
University of Pittsburgh
Results
Apollo use over 2 weeks significantly improved symptom scores in subjects with PTSD
Population
Adults with diagnosed PTSD (Ages 18-58)
Sample Size
16
Primary Outcomes
Change in PTSD symptoms and HRV before and after Apollo use.
Studies in progress
Transcranial Magnetic Stimulation (TMS) Therapy for Treatment-Resistant Depression and PTSD
Partner
Mytransformations, LLC
Status
IRB approved, not recruiting
Sample Size
100
Population
Ages 18+ clinically diagnosed for at least one of the following conditions: Major Depressive Disorder (MDD), recurrent, Treatment-resistant depression (TRD), Post-traumatic stress disorder (PTSD). Have been prescribed transcranial magnetic stimulation (TMS)
Primary Outcomes
Examine whether the Apollo device can help improve treatment response rates in patients with TRD and/or PTSD in undergoing TMS compared to TMS alone.
Secondary Outcomes
Examine whether use of the Apollo device after completion of the TMS therapy retains or improves patient outcomes.
A Wearable Wrist-Worn Nerve Stimulator for Remediating Autonomic Dysfunction Associated Chronic Migraine/Headache and Mood Disturbance in Adolescents
Partner
University of South Carolina
Status
IRB approved, not recruiting
Sample Size
60
Population
Clinic patients (ages 10+) who the clinicians have diagnosed with chronic headache/migraine and deemed suitable for the use of the device
Primary Outcomes
Evaluate the effectiveness of the Apollo Device for remediating clinical symptoms including pain, anxiety, depression and sleep disturbance via comparison of scores at initial evaluation and follow-up appointments.
Acute Nerve Stimulation for Enhancing Human and Cognitive Performance
Partner
University of South Carolina
Status
IRB approved, not recruiting
Sample Size
35
Population
Recreationally active adults (age 18-35). ROTC from The University of South Carolina and Benedict College
Primary Outcomes
The purpose of this within subject, repeated measures study is to evaluate the effectiveness of Apollo’s stimulation compared to sham stimulation. The main outcome of interest is the Apollo Neuro Device’s influence on physiological function to mediate human performance and cognition. Physiological function will be derived from metrics of heart rate variability and blood-based biomarkers, whilst human performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.
Long Covid
Partner
The Board of Medicine
Status
IRB approved, recruiting
Sample Size
TBD
Population
Age 18 or over. Currently experiencing symptoms related to post-COVID conditions
Primary Outcomes
Evaluate the impact of Apollo wearable use on symptomology in people experiencing post-COVID conditions.
Secondary Outcomes
Evaluate the impact of Apollo wearable use on quality of life in people experiencing post-COVID conditions.
Ketamine Therapy First Responder Study
Partner
Pamela Kryskow
Status
IRB approved, recruiting
Sample Size
TBD
Population
Age 18 or over. First responders enrolled in ketamine therapy.
Primary Outcomes
To evaluate the effect of the Apollo Neuro device on treatment resistant anxiety disorders in participants in the 12 week Ketamine Assisted Therapy program (RTT-KAT).
Secondary Outcomes
To determine whether the Apollo Neuro device enhances the success of the RTT-KAT treatment program for participants with treatment resistant anxiety disorders.
Retrospective ŌURA Study
Partner
Apollo Neuroscience (internal study)
Status
IRB approved, not recruiting
Sample Size
TBD
Population
At least one day of summary data from the ŌURA ring prior to Apollo wearable use; and, at least one day of summary data from the ŌURA ring after Apollo wearable use.
Primary Outcomes
Evaluate the impact of Apollo wearable use on sleep metrics as measured by the ŌURA Ring device.
Secondary Outcomes
Evaluate the impact of Apollo wearable use on cardiovascular metrics as measured by the ŌURA Ring device.
Open-Label Trial of Apollo in Veterans with Post-Traumatic Stress Disorder (PTSD)
Partner
Rocky Mountain VA Hospital, MIRECC for Suicide Prevention
Status
Recruitment Open (Local participants only)
Sample Size
100
Population
Veterans (age 18-65) eligible to receive care by a VA provider
Primary Outcomes
To test the acceptability and feasibility of the Apollo wearable system for managing symptoms in Veterans with PTSD.
Secondary Outcomes
Inflammatory biomarkers, microbiome, stress response gene expression.
Open-Label Clinical Trial of Apollo to Sustain Remission in Treatment-Resistant PTSD following MDMA-Assisted Therapy
Partner
The Board of Medicine
Status
Recruitment Open (Eligible Remote Participants)
Sample Size
200
Population
Any past participant in a MAPS trial of MDMA-assisted therapy who has completed their final follow up period with MAPS, including participants who received placebo and those who dropped out of the study prior to completion, are eligible to participate.
Primary Outcomes
To examine how use of Apollo can influence PTSD symptoms and remission rates over two years after participation in any MAPS trial of MDMA-assisted therapy.
Double-Blind Randomized Placebo-Controlled Trial of Apollo to Reduce Symptoms of ADHD/ADD
Partner
Michigan State University
Status
Recruitment Open (Local participants only)
Sample Size
100
Population
Children and Young Adults (7-17yo)
Primary Outcomes
To examine the effect of wearing Apollo on symptoms associated with ADHD.
Secondary Outcomes
To examine the effect of wearing Apollo on medication use associated with ADHD.
Remote Real World Observational Sleep Study of the Apollo Wearable
Partner
The Board of Medicine
Status
Recruitment Open (Eligible Remote participants)
Sample Size
6000
Population
Any Apollo wearable and ŌURA Ring user over age 18
Primary Outcomes
To examine the impact of Apollo usage on users' sleep and cardiovascular metrics as measured by validated survey tools and biometric data captured by the ŌURA Ring.
Open-Label Trial of Apollo for Treatment-Resistant Cancer Pain and Fatigue
Partner
University of Pittsburgh Medical Center
Status
Recruitment Open (Local participants only)
Sample Size
30
Population
Adults age 18-100 with metastatic breast cancer and fatigue
Primary Outcomes
To evaluate the efficacy and tolerability of the Apollo device in the management of fatigue and pain in patients with Metastatic Breast Cancer.
A Wearable Wrist-Worn Nerve Stimulator for Remediating Persistent Symptoms in Adolescents with PCS and Chronic Headache
Partner
University of South Carolina & The Board of Medicine
Status
Recruitment Open(Local Participants)
Sample Size
100
Population
Adolescents with PCS and Chronic Headache
Primary Outcomes
Examine how Apollo wearable use in participants with Post Concussion Syndrome (PCS) impacts their treatment outcomes in clinic and overall symptomatology.
Open-Label Trial of Apollo to Improve Recovery and Prevent Burnout in Physicians
Partner
University of Pittsburgh & University of California Los Angeles
Status
Recruitment Open at UPMC
Sample Size
500
Population
Any physician currently in clinical practice or training at UPMC or UCLA
Primary Outcomes
This study is aimed at evaluating the impact of HRV-improving technology on physician well being, namely subjective and objective measures of stress and recovery among physicians.
Secondary Outcomes
Biometric data on cardiovascular fitness (HR/HRV) and sleep collected from ŌURA Ring and Apple Health.
Continuous Blood Pressure Monitoring with and without Vibratory Ankle Bracelet in Human Volunteers
Partner
BioActive (BAS)
Status
Recruitment Open
Sample Size
21
Population
General population age 18-65
Primary Outcomes
To examine if the Apollo wearable will reliably improve cardiovascular function in healthy subjects.
Secondary Outcomes
To examine whether heart rate variability (HRV) will change before and after the vibratory stimulation by Apollo.
